Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Front Immunol ; 14: 1155770, 2023.
Article in English | MEDLINE | ID: covidwho-20244319

ABSTRACT

Introduction: Many people with long COVID symptoms suffer from debilitating neurologic post-acute sequelae of SARS-CoV-2 infection (Neuro-PASC). Although symptoms of Neuro-PASC are widely documented, it is still unclear whether PASC symptoms impact virus-specific immune responses. Therefore, we examined T cell and antibody responses to SARS-CoV-2 Nucleocapsid protein to identify activation signatures distinguishing Neuro-PASC patients from healthy COVID convalescents. Results: We report that Neuro-PASC patients exhibit distinct immunological signatures composed of elevated CD4+ T cell responses and diminished CD8+ memory T cell activation toward the C-terminal region of SARS-CoV-2 Nucleocapsid protein when examined both functionally and using TCR sequencing. CD8+ T cell production of IL-6 correlated with increased plasma IL-6 levels as well as heightened severity of neurologic symptoms, including pain. Elevated plasma immunoregulatory and reduced pro-inflammatory and antiviral response signatures were evident in Neuro-PASC patients compared with COVID convalescent controls without lasting symptoms, correlating with worse neurocognitive dysfunction. Discussion: We conclude that these data provide new insight into the impact of virus-specific cellular immunity on the pathogenesis of long COVID and pave the way for the rational design of predictive biomarkers and therapeutic interventions.


Subject(s)
CD4-Positive T-Lymphocytes , CD8-Positive T-Lymphocytes , COVID-19 , Post-Acute COVID-19 Syndrome , Humans , COVID-19/immunology , Interleukin-6 , Post-Acute COVID-19 Syndrome/immunology , SARS-CoV-2
2.
J Infect Dis ; 2022 Jul 27.
Article in English | MEDLINE | ID: covidwho-2324022

ABSTRACT

BACKGROUND: The development of memory B cells after asymptomatic SARS-CoV-2 infection is not well understood. METHODS: We compared Spike antibody titers, pseudovirus neutralizing antibody titers, and memory B cell responses among SARS-CoV-2 PCR positive Marine recruits who either reported asymptomatic or symptomatic infection. RESULTS: 36 asymptomatic participants exhibited similar Spike IgG titers, Spike IgA titers, and pseudovirus neutralization titers compared to 30 symptomatic participants. Pseudovirus neutralization and Spike IgG titers showed significant positive correlations with frequency of memory B cells. CONCLUSIONS: Among young adults, asymptomatic SARS-CoV-2 infection induced antibody and memory B cell responses comparable to mild symptomatic infection.

3.
Coronaviruses ; 2(5):1-5, 2021.
Article in English | EMBASE | ID: covidwho-2272499

ABSTRACT

Background: Many observations denote that we should deal with COVID-19 as a systemic disease. Method(s): In the following report, we briefly discuss observations denoting "the systemic" nature of COVID-19. Result(s): COVID-19 virology, the roles of ACE-2 receptor in COVID-19 pathogenesis, immunolog-ical aspects of the disease, endothelial dysfunction and coagulopathy, and autopsy studies denote the systemic nature of COVID-19. Conclusion(s): Thinking of COVID-19 as a systemic disease, we will implement our ways of understanding and hence dealing with that disease. The most important public health solution is an effective vaccine for the broad population remaining at risk. As patients with COVID-19 present a broad spectrum of clinical presentation and distinct phenotypes, different strategies of management should be customized to the specific individual phenotypes. Further researches are highly needed to clarify the concept of "Is COVID-19 a systemic disease?". Until that time, we think that clinicians should deal with COVID-19 as a systemic disease.Copyright © 2021 Bentham Science Publishers.

4.
Religions ; 14(3), 2023.
Article in English | Scopus | ID: covidwho-2253098

ABSTRACT

From the systemic issues of race and class division to political partisanship and religious identity, the pandemic has affected many aspects of American social and political life. I interrogate the role that religions have played in communal identity-making during the pandemic, and how such identities shaped ideological responses, particularly in the US, stymying public health efforts to stop, or at least significantly slow, the spread of COVID-19. Drawing from Gabriel Garcia Marquez's Love in the Time of Cholera as a historical case study, I use Garcia Marquez's depiction of religion's identity-making power during the cholera pandemic depicted in the novel as a comparison by which to understand current experiences of white Evangelical Christians in America during the current COVID-19 pandemic, particularly those who reject risk-minimizing practices such as mask wearing, quarantining, and vaccination. Drawing both from representations of Roberto Esposito's theory of immunity and community, and from Lauren Berlant's concept of "cruel optimism”, as well as sociological understandings of religion and identity, I argue that the boundary-making practices of religion and of communal and national identity are related to the complex and often contradictory set of moral practices that led many white Evangelicals to disregard public health policies surrounding COVID-19. A concurrent analysis of Garcia Marquez's novel and of current events will allow me to explore this phenomenon, as Lauren Berlant would put it, both through the historically affective aesthetic and through the affective present. © 2023 by the author.

5.
European Journal of Neurodegenerative Diseases ; 11(1):2014/10/01 00:00:00.000, 2022.
Article in English | EMBASE | ID: covidwho-2230114

ABSTRACT

In December of 2019, SARS-CoV-2 surfaced and the global COVID-19 pandemic began. The pandemic has had far-reaching effects, socially, economically, and especially for healthcare, presenting challenges to patients with neuroinflammatory disorders. Apart from the well-known respiratory, pulmonary, and cardiovascular symptoms that COVID-19 is responsible for, studies continue to show its role in generating neuroinflammation and the different neurological effects that can arise. This review summarizes the relationship between the COVID-19 pandemic and neuroinflammatory diseases, with an emphasis on the effects on patients with neuroinflammatory disorders. Copyright © 2022, Biolife s.a.s.. All rights reserved.

6.
European Journal of Neurodegenerative Diseases ; 11(1):10-14, 2022.
Article in English | EMBASE | ID: covidwho-2218636

ABSTRACT

In December of 2019, SARS-CoV-2 surfaced and the global COVID-19 pandemic began. The pandemic has had far-reaching effects, socially, economically, and especially for healthcare, presenting challenges to patients with neuroinflammatory disorders. Apart from the well-known respiratory, pulmonary, and cardiovascular symptoms that COVID-19 is responsible for, studies continue to show its role in generating neuroinflammation and the different neurological effects that can arise. This review summarizes the relationship between the COVID-19 pandemic and neuroinflammatory diseases, with an emphasis on the effects on patients with neuroinflammatory disorders. Copyright © 2022, Biolife s.a.s.. All rights reserved.

7.
Health Expect ; 25(6): 2645-2657, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-2052474

ABSTRACT

INTRODUCTION: Already in its first implementation, the introduction of the Covid-19 immunity certificate has generated some debate among the public. This debate might be a hindrance to the effective realization of this policy. This study aimed to systematically review published research evaluating public feeling of the Covid-19 immunity certificate policy measure and to find which factors might influence its acceptance. METHODS: We followed the scoping review methods manual by the Joanna Briggs Institute. We included studies with no time limits that presented novel data, and no exclusions have been made based on study design. We excluded articles that presented just expert opinions. RESULTS: We found and reviewed 17 articles. The included studies were conducted in two main countries (the United Kingdom and Switzerland), with the rest from Israel, Italy, Spain, Germany, Australia, Taiwan and China. Both qualitative and quantitative studies were included, and nonrepresentative samples were mostly used to explore the public feeling about the Covid-19 immunity certification. The included studies showed that public views on immunity certification are quite contradictory and influenced by age, gender, ethnicity, political orientation and attitudes towards Covid-19 vaccination. The topic more often addressed by the included studies was the public's views on the positive and negative implications of the Covid-19 immunity certificate in terms of ethical, legal and behavioural consequences of this measure. CONCLUSION: The varying acceptance rates are notable and may partly be linked to differences in demographics, Covid-19 concerns and ideological beliefs, as seen in other health-related tracking policies. Moreover, dominant factors behind the (un)success of this policy are complex and entangled with the cultural and political dimensions rather than being just technical. For this reason, it is important to expand psychosocial research to better understand the concerns behind health certifications and allow planning of culturally based and ethically sound suitable strategies. This would be very relevant to increasing public approval and compliance with this public health measure. PATIENT OR PUBLIC CONTRIBUTION: This does not apply to our work as it was a review paper.


Subject(s)
COVID-19 , Humans , COVID-19 Vaccines , Health Policy , Morals , Attitude
8.
Int J Infect Dis ; 122: 850-854, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-1882084

ABSTRACT

BACKGROUND: Scarce information is available regarding the long-term immunogenicity of the Sputnik V vaccine. Here Sputnik V vaccinated subjects were evaluated 6 months after receiving the 2-dose prime-boost schedule. METHODS: Eighty-six hospital workers from Venezuela, 32 with a previous COVID-19 infection and 54 SARS-CoV-2 naïve subjects, were enrolled. IgG antibodies levels against the wild-type Receptor Binding Domain (RBD) were measured in an ELISA and with an in vitro ACE2-surrogate RBD binding inhibition assay at day 42 and day 180 after receiving the second dose. IgG levels were expressed in BAU/ml. Binding inhibition antibodies were expressed in IU/ml. RESULTS: On average, RBD-IgG levels decreased by approximately 50% between the two time-points in the COVID-19 naïve cohort (geometric mean concentration (GMC) 675 BAU/mL vs. 327 BAU/ml) and decreased by approximately 25% in the previously infected cohort (GMC 1209 BAU/mL vs 910 BAU/ml). Within our cohort, 94% showed a "good to excellent" neutralizing activity measured with the in vitro test 6 months after vaccination. CONCLUSIONS: The Sputnik V vaccine provided long-term and durable humoral immunity in our cohort specially if a person has been both vaccinated and had a previous infection with SARS-CoV-2.


Subject(s)
COVID-19 , Viral Vaccines , Animals , Antibodies, Viral , Antibody Formation , COVID-19/prevention & control , Health Personnel , Humans , Immunoglobulin G , Mice , Mice, Inbred BALB C , SARS-CoV-2 , Vaccination , Venezuela
9.
Mol Ther ; 30(9): 2984-2997, 2022 09 07.
Article in English | MEDLINE | ID: covidwho-1805354

ABSTRACT

As the coronavirus disease 2019 (COVID-19) pandemic continues and new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern emerge, the adaptive immunity initially induced by the first-generation COVID-19 vaccines starts waning and needs to be strengthened and broadened in specificity. Vaccination by the nasal route induces mucosal, humoral, and cellular immunity at the entry point of SARS-CoV-2 into the host organism and has been shown to be the most effective for reducing viral transmission. The lentiviral vaccination vector (LV) is particularly suitable for this route of immunization owing to its non-cytopathic, non-replicative, and scarcely inflammatory properties. Here, to set up an optimized cross-protective intranasal booster against COVID-19, we generated an LV encoding stabilized spike of SARS-CoV-2 Beta variant (LV::SBeta-2P). mRNA vaccine-primed and -boosted mice, with waning primary humoral immunity at 4 months after vaccination, were boosted intranasally with LV::SBeta-2P. A strong boost effect was detected on cross-sero-neutralizing activity and systemic T cell immunity. In addition, mucosal anti-spike IgG and IgA, lung-resident B cells, and effector memory and resident T cells were efficiently induced, correlating with complete pulmonary protection against the SARS-CoV-2 Delta variant, demonstrating the suitability of the LV::SBeta-2P vaccine candidate as an intranasal booster against COVID-19. LV::SBeta-2P vaccination was also fully protective against Omicron infection of the lungs and central nervous system, in the highly susceptible B6.K18-hACE2IP-THV transgenic mice.


Subject(s)
COVID-19 , Viral Vaccines , Animals , Antibodies, Neutralizing , Antibodies, Viral , COVID-19/prevention & control , COVID-19 Vaccines , Humans , Lung , Mice , Mucous Membrane , SARS-CoV-2/genetics , Vaccination , Vaccines, Synthetic , mRNA Vaccines
10.
J Community Hosp Intern Med Perspect ; 11(6): 733-739, 2021.
Article in English | MEDLINE | ID: covidwho-1517743

ABSTRACT

The COVID-19 pandemic has altered innumerable lives. Although recent mass vaccinations offer a glimmer of hope, the rising death toll and new variants continue to dominate the current scenario. As we begin to understand more about SARS-CoV-2 infections, the territory of reinfections with COVID-19 remains unexplored. In this review, we will discuss several aspects of reinfection: (a) How is COVID-19 reinfection characterized? (b) Does prior literature differentiate between reinfection and reactivation? (c) What SARS-CoV-2 strains do the vaccines target and can they protect against new strains? Larger and longer timeline studies are needed to understand reinfection risks. With the ongoing distribution of the SARS-CoV-2 vaccines to provide protection, the understanding of the possibility for SARS-CoV-2 reinfection remains critical. Abbreviations CDC: Centers for Disease ControlSARS-CoV-2: Severe acute respiratory syndrome coronavirus 2COVID-19: Coronavirus disease 2019RT-PCR: Reverse Transcription Polymerase Chain ReactionPASC: Post-Acute Sequelae of SARS-CoV-2 infection.

11.
Healthcare (Basel) ; 9(9)2021 Aug 30.
Article in English | MEDLINE | ID: covidwho-1390581

ABSTRACT

BACKGROUND: COVID-19 antibody testing has been shown to be predictive of prior COVID-19 infection and an effective testing tool. The CLUNGENE® SARS-COV-2 VIRUS (COVID-19) IgG/IgM Rapid Test Cassette was evaluated for its utility to aide healthcare professionals. METHOD: Two studies were performed by using the CLUNGENE® Rapid Test. (1) An expanded Point-of-Care (POC) study at two clinical sites was conducted to evaluate 99 clinical subjects: 62 positive subjects and 37 negative subjects were compared to RT-PCR, PPA, and NPA (95% CI). Sensitivity was calculated from blood-collection time following symptom onset. (2) A cross-reactivity study was performed to determine the potential for false-positive results from other common infections. RESULTS: The specificity of subjects with confirmed negative COVID-19 by RT-PCR was 100% (95% CI, 88.4-100.0%). The sensitivity of subjects with confirmed positive COVID-19 by RT-PCR was 96.77% (95% CI, 88.98-99.11%). In the cross-reactivity study, there were no false-positive results due to past infections or vaccinations unrelated to the SARS-CoV-2 virus. CONCLUSION: There is a need for a rapid, user-friendly, and inexpensive on-site monitoring system for diagnosis. The CLUNGENE® Rapid Test is a useful diagnostic test that provides results within 15 min, without high-complexity laboratory instrumentation.

12.
Int J Infect Dis ; 110: 171-178, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1320157

ABSTRACT

OBJECTIVE: The objective of this study was to determine the proportion of the Anambra State population that had been infected by the SARS-CoV-2 virus and developed antibodies before the second wave. METHODS: The WHO-recommended health facility-based cross-sectional approach was adapted for this survey. Between 8th and 15th December 2020, 3142 participants across the 21 local government areas (LGAs) of the State, aged one year and over, attending randomly selected health facilities, were recruited. Demographic and symptom-related information were collected from the participants as well as whole peripheral blood, which was tested for SARS-CoV-2 IgG and IgM with rapid test kits. RESULTS: 425 participants tested positive for IgG only, 74 for IgM only, while 54 were positive for both IgG and IgM. Overall, 553 positives were recorded, giving a crude seroprevalence of 17.6% (95% CI = 16.26 - 18.98). It ranged widely from 31.9% (95% CI = 24.43 - 40.22) in Onitsha North LGA to 5.4% (95% CI = 2.19 - 10.78) in Awka north. Bayesian Adjustments yielded a state seroprevalence of 16.1%. CONCLUSION: One in six state residents had been infected by SARS-CoV-2 and developed antibodies before the second wave. All LGAs, age groups, sexes, and settlement types were affected by COVID-19. A large proportion of the population remained susceptible to SARS-CoV-2.


Subject(s)
COVID-19 , SARS-CoV-2 , Antibodies, Viral , Bayes Theorem , Humans , Nigeria/epidemiology , Seroepidemiologic Studies
13.
Allergy ; 75(10): 2445-2476, 2020 10.
Article in English | MEDLINE | ID: covidwho-614472

ABSTRACT

With the worldwide spread of the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) resulting in declaration of a pandemic by the World Health Organization (WHO) on March 11, 2020, the SARS-CoV-2-induced coronavirus disease-19 (COVID-19) has become one of the main challenges of our times. The high infection rate and the severe disease course led to major safety and social restriction measures worldwide. There is an urgent need of unbiased expert knowledge guiding the development of efficient treatment and prevention strategies. This report summarizes current immunological data on mechanisms associated with the SARS-CoV-2 infection and COVID-19 development and progression to the most severe forms. We characterize the differences between adequate innate and adaptive immune response in mild disease and the deep immune dysfunction in the severe multiorgan disease. The similarities of the human immune response to SARS-CoV-2 and the SARS-CoV and MERS-CoV are underlined. We also summarize known and potential SARS-CoV-2 receptors on epithelial barriers, immune cells, endothelium and clinically involved organs such as lung, gut, kidney, cardiovascular, and neuronal system. Finally, we discuss the known and potential mechanisms underlying the involvement of comorbidities, gender, and age in development of COVID-19. Consequently, we highlight the knowledge gaps and urgent research requirements to provide a quick roadmap for ongoing and needed COVID-19 studies.


Subject(s)
Betacoronavirus/immunology , Clinical Laboratory Techniques/methods , Coronavirus Infections/diagnosis , Coronavirus Infections/immunology , Pneumonia, Viral/diagnosis , Pneumonia, Viral/immunology , Academies and Institutes , COVID-19 , COVID-19 Testing , Coronavirus Infections/pathology , Humans , Pandemics , Pneumonia, Viral/pathology , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL